Diagnostic and Interventional Cardiology DAIC

Diagnostic and Interventional Cardiology (DAIC) is a magazine that reaches more than 25,000 healthcare professionals in cardiology, interventional cardiology and cath labs across the United States. These influential buying team members rely on DAIC's award-winning editorial content and comparison charts as a unique research tool for specifying, recommending and approving technology/device purchases.

Reduction in the risk of death or major bleeding after primary PCI in patients with STEMI treated with heparin monotherapy (blue curve) or bivalirudin with a post-procedure infusion (red curve). The hazard ratio of 0.69 signifies a 31% reduction in risk. The ARR (absolute risk reduction) was 1.3%. The NNT (number of patients needed to treat to prevent one death or large bleed) was 76. Image courtesy of Mount Sinai Health System

News | Antiplatelet and Anticoagulation Therapies

Bivalirudin Found to be Safer and More Effective Than Heparin for Treating Heart Attack Patients Undergoing Percutaneous Coronary Intervention

November 14, 2022 — Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the ...

November 14, 2022

The "Trending Topics at Sessions 2022" panel of experts featured Manesh R. Patel, MD, FACC, FAHA, Chair of the Committee on AHA 2022 Scientific Sessions, to review highlights and lessons learned from the event.

News | AHA

November 14, 2022 — The American Hospital Association Scientific Sessions 2022, held Nov. 5-7 in Chicago, IL, presented ...

November 14, 2022

Risk Reductions of 46% to 52% for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30- and 90-Days Following Hospital Discharge

News | Heart Failure

New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure

November 9, 2022 — Lexicon Pharmaceuticals, Inc. announced that a new analysis of results from the SOLOIST-WHF Phase 3 ...

November 09, 2022

News | Hypertension

CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific Sessions

November 9, 2022 — CinCor Pharma, Inc. announced the presentation today of Phase 2 data from its BrigHtn trial as part ...

November 09, 2022

Feature | Angiography | By Bhvita Jani

Interventional X-ray and Mobile C-arm Equipment Markets Had a Double-digit Recovery in 2021

The world market for interventional X-ray and mobile C-arm equipment is forecast to reach over $4.9 billion by 2026 ...

November 09, 2022

Tech tools are creating positive change in Cardiac MRI Software Market

Feature | Magnetic Resonance Imaging (MRI) | By Christine Book

AI-powered Software Solutions Enhance Cardiac Diagnostics

Interventional cardiologists know well the phrase “change is the only constant.” This is especially relevant as ...

November 09, 2022

Artificial intelligence-powered alternative data is driving novel and disruptive market research opportunities at a staggering clip amid category growth forecasts, prompting industries of every size and sort to capitalize on this strategy that’s ever evolving and innovating

Feature | Cardiovascular Business | By Merilee Kern, MBA

AI-Powered Alternative Data Driving Extreme Market Research Disruption

Numerous indicators make clear that the next five years will usher in extreme transformation for a multitude of ...

November 09, 2022

In 2023, the DAIC/dicardiology.com team looks to enhance its educational offerings to build the resources you need and have been asking for.

Blog | Cardiovascular Business

Enhancing the Educational Experience

Reflecting back, 2022 has been a productive year. It brought with it many changes and challenges, but also brought back ...

November 09, 2022

Robert J. Mentz, M.D., Associate Professor of Medicine, Chief, Heart Failure Section, Associate Program Director, Duke Cardiology Fellowship, Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, image copyright Robert J. Mentz

News | AHA

TRANSFORM-HF Trial Found No Difference in Effectiveness Between 2 Common Loop Diuretics

November 8, 2022 — After hospital discharge for heart failure, people treated with either loop diuretic medication ...

November 08, 2022

Julian D. Gillmore, M.D., Ph.D., Professor, University College London Centre for Amyloidosis, United Kingdom, image copyright University College London Centre for Amyloidosis

News | AHA

Novel Gene-Editing Therapy Shows Promise For Patients With Transthyretin Amyloid Cardiomyopathy

November 8, 2022 — A single IV infusion of NTLA-2001, a novel CRISPR/Cas9-based gene editing therapy, significantly ...

November 08, 2022

Petr Ostadal, M.D., Ph.D., Professor of Medicine, Department of Cardiology, Na Homolce Hospital, Czech Republic. Image copyright Na Homolce Hospital

News | AHA

Early Use of ECMO devices Did Not Improve Outcomes in People With Cardiogenic Shock

November 7, 2022 — The immediate use of veno-arterial mechanical circulatory extracorporeal membrane oxygenation (ECMO) ...

November 07, 2022

New guidance covers recommendations for surgery, imaging, family screening, and the importance of a multidisciplinary team

News | ACC

AHA and ACC Issue New Guideline on Aortic Disease

Nov. 4, 2022 — The American College of Cardiology and the American Heart Association have published a new guideline on ...

November 05, 2022

Fig. 1. Selective reduction of succinyl-CoA among the TCA cycle metabolites in cardiac muscle during chronic HF. Relative levels of the TCA cycle metabolites in cardiac muscles isolated from myocardial infarction (MI) mice, compared with those from sham mice, 28 d after surgery. Each data point in the dot plot represents one individual mouse sample (n = 38 for both groups for all metabolites, except for succinyl-CoA in which n = 18 for both groups). Concentrations of succinyl-CoA in these samples were 2.2–5

News | Heart Failure

How Heart Failure Disrupts the Cell's Powerhouse

November 3, 2022 — Chronic heart failure causes the cell’s powerhouses to dysfunction, in part due to overconsumption of ...

November 03, 2022

Videos | TCT

VIDEO: Clinical Science in Structural Heart Disease

At TCT 2022, Jane Leopold, MD, a cardiologist at Brigham and Women’s Hospital; Director, Women's Interventional ...

November 03, 2022

About one-fifth of implants of left ventricular-assist devices have the complication of right heart failure. Abbott Laboratories (adapted)

News | Ventricular Assist Devices (VAD)

Study Sifts Potential Factors of Device-Implant Complication

November 2, 2022 — For decades, left ventricular-assist devices (LVADs) have extended the lives of people whose hearts ...

November 02, 2022